BeiGene
Cell Therapy as a Pillar of Future Therapeutics, an Interview with Alex Huang, Vice President and Head of Cell Therapy at BeiGene
2022-10-05
Novartis Licenses BeiGene’s Antibody for a Potential $2.8 Billion After Its Own Drug Disappoints
2021-12-21
BeiGene’s Brukinsa Bags Second FDA Approval, to Rival Imbruvica in Treating a Rare Cancer
2021-09-06